16 December 2020
Analysts at Welp Magazine have named Medannex as one of the most promising companies currently operating in the Clinical Trials space in the UK.
Chosen for exceptional growth and innovation, this is a great endorsement of the progress Medannex has made since its Series B fundraise in 2019.
The Medannex team is currently preparing for a First-in-Human clinical study of the company’s lead antibody therapy, MDX-124, to be initiated in 2021.